1675203-84-5

Basic information

• Product Name: PD-L1 inhibitor 1
• Synonyms: PD-L1 inhibitor 1;PD1-PDL1 inhibitor 2;N-[2-[[[2-Methoxy-6-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]-3-pyridinyl]methyl]amino]ethyl]acetamide;BMS-202;Acetamide, N-[2-[[[2-methoxy-6-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]-3-pyridinyl]methyl]amino]ethyl]-
• CAS NO: 1675203-84-5
• Molecular Formula: C25H29N3O3
• Molecular Weight: 419.51606
• EINECS: -0
• Mol File: 1675203-84-5.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 611.4±55.0 °C(Predicted)
• Appearance: /
• Density: 1.133±0.06 g/cm3(Predicted)
• Storage Temp.: -20°C
• Solubility: Soluble in DMSO (up to at least 25 mg/ml) or in Ethanol (up to at least 25 mg/ml)
• PKA: 16.06±0.46(Predicted)
• Stability: Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.
• CAS DataBase Reference: PD-L1 inhibitor 1(CAS DataBase Reference)
• NIST Chemistry Reference: PD-L1 inhibitor 1(1675203-84-5)
• EPA Substance Registry System: PD-L1 inhibitor 1(1675203-84-5)

Safety Data

• Hazardous Substances Data: 1675203-84-5(Hazardous Substances Data)

Usage

Description

The programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) interaction plays a dominant role in the suppression of T cell responses, especially in a tumor microenvironment, protecting tumor cells from lysis. PD-1/PD-L1 inhibitor 2 is reported to prevent the interaction of PD-L1 with PD-1 with an IC50 value of 18 nM.

Uses

BMS-202 is a Novel inhibitor of the PD-1/PD-L1 interaction by inducing PD-L1 dimerization through PD-1 interacting surface.

References

1) Zak?et al.?(2016),?Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1);?Oncotarget?7?30323 2) Guzik?et al.?(2017),?Small-molecule inhibitors of the programmed cell death -1/programmed cell death -ligand 1(PD-1/PD-L1) interaction via transiently induced protein states and dimerization of PD-L1;?J. Med. Chem.?60?5857

Upstream product

• 95652-81-6 6-chloro-2-methoxy-3-pyridinecarboxaldehyde 
• 76350-90-8 (2-methyl-[1,1′-biphenyl]-3-yl)methanol 
• 1001-53-2 monoacetylaminoethylamine 
• 83647-43-2 3-bromo-2-methylbenzyl alcohol 
• 98-80-6 phenylboronic acid 

Relevant articles and documents

Design, synthesis, evaluation, and structural studies of C2-Symmetric Small molecule inhibitors of programmed cell death-1/programmed death-ligand 1 protein-protein interaction

A series of C2-symmetric inhibitors was designed and evaluated for inhibitory activity against the programmed cell death-1/programmed death-ligand 1(PD-1/PD-L1) protein-protein interaction (PPI) in a homogenous time-resolved fluorescence (HTRF) assay and PD-1 signaling in cell-based coculture assays. C2-symmetric inhibitors 2a (LH1306) and 2b (LH1307) exhibited IC50 values of 25 and 3.0 nM, respectively, in the HTRF assay. While 2a was ～3.8-fold more potent than previously reported inhibitor 1a, 2b could not be differentiated from 1b due to their high potency and the limit of our HTRF assay conditions. In one cell-based coculture PD-1 signaling assay, 2a and 2b were 8.2- and 2.8-fold more potent in inhibiting PD-1 signaling than 1a and 1b, respectively. NMR and X-ray cocrystal structural studies provided more structural insights into the interaction between 2b and PD-L1; 2b binds to PD-L1 at the PD-1 binding site and induces the formation of a more symmetrically arranged PD-L1 homodimer than that previously reported for other inhibitors.